<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03899779</url>
  </required_header>
  <id_info>
    <org_study_id>NL67607.068.18</org_study_id>
    <secondary_id>852001924</secondary_id>
    <secondary_id>METC18-037</secondary_id>
    <nct_id>NCT03899779</nct_id>
  </id_info>
  <brief_title>Face-to-face Versus Online Hypnotherapy for the Treatment of Irritable Bowel Syndrome</brief_title>
  <acronym>FORTITUDE</acronym>
  <official_title>Face-to-face Versus Online Hypnotherapy for the Treatment of Irritable Bowel Syndrome, According to a Non-inferiority Design. Three-armed Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Psychological therapies are effective in reducing irritable bowel syndrome (IBS) symptom
      severity and increasing quality of life and are recommended for the management of IBS by
      guidelines. Evidence appears strongest for the efficacy of hypnotherapy as psychological
      treatment. However, therapist-led interventions are time consuming and relatively costly.
      Approaches based on e-health are cost saving and appear more attractive to patients as no
      visits to a therapist are necessary. Therefore, the investigators plan to conduct a
      multicentre randomised controlled trial to examine whether the effectiveness of online
      hypnotherapy is non-inferior compared to individual face-to-face hypnotherapy delivered by a
      therapist, according to current FDA guidelines. Online psychoeducation will be used as
      control condition. In addition, the investigators hypothesize that treatment with online
      hypnotherapy is a more cost-effective therapy than face-to-face hypnotherapy in IBS patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 8, 2019</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Abdominal pain response rate after 12 weeks of treatment</measure>
    <time_frame>12 weeks</time_frame>
    <description>A responder is defined as a patient who experiences at least a 30 percent decrease in the weekly average of worst daily abdominal pain (measured daily, on an 11 point NRS) compared to baseline weekly average in at least 50 percent of the weeks in which the treatment in given.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Degree of relief response rate after 12 weeks of treatment</measure>
    <time_frame>12 weeks</time_frame>
    <description>A responder is defined as a patient who experiences a weekly relief of 1 or 2 (on a 7 point NRS) in at least 50 percent of the weeks in which treatment is given.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of symptom severity</measure>
    <time_frame>16 weeks</time_frame>
    <description>determined by the Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS) by 50 points or more [IBS-SSS, minimum score 0, maximum score 500]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indirect costs</measure>
    <time_frame>16 weeks and after 6 months and 1 year follow-up</time_frame>
    <description>determined by Productivity Cost Questionnaire (PCQ) (savings from increased work productivity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Direct costs</measure>
    <time_frame>16 weeks and after 6 months and 1 year follow-up</time_frame>
    <description>determined by Medical Consumption Questionnaire (MCQ) (savings from reduced medical resource use)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General Quality of life (by EQ-5D)</measure>
    <time_frame>16 weeks and after 6 months and 1 year follow-up</time_frame>
    <description>Determined by the Euro-Quality of Life - 5 domains (EQ-5D-5L) (change from baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IBS related Quality of life (by IBS-QoL)</measure>
    <time_frame>16 weeks and after 6 months and 1 year follow-up</time_frame>
    <description>Determined by IBS Quality of Life (IBS-QoL) (change from baseline) [IBS-QoL, minimum score: 0, maximum score 100]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of over the counter medication and rescue medication</measure>
    <time_frame>12 and 16 weeks</time_frame>
    <description>As reported via digital diary (mobile phone application)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and severity of side effects</measure>
    <time_frame>12 and 16 weeks</time_frame>
    <description>As reported via digital diary (mobile phone application)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expectation</measure>
    <time_frame>16 weeks</time_frame>
    <description>Response rates in relation to patient expectation prior to the start of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rates in relation to comorbid anxiety</measure>
    <time_frame>16 weeks and after 6 months and 1 year follow-up</time_frame>
    <description>Assessed with the use of the Generalized Anxiety Disorder-7 (GAD-7). [GAD-7 minimum score: 0, maximum score: 21]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rates in relation to comorbid depression</measure>
    <time_frame>16 weeks and after 6 months and 1 year follow-up</time_frame>
    <description>Assessed with the use of the Patient Health Questionnaire-9 (PHQ-9). [PHQ-9 minimum score: 0, maximum score: 21]</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">285</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Face-to-face hypnotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>12 weeks treatment with face-to-face hypnotherapy (6 individual, bi-weekly sessions)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Online hypnotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks treatment with online hypnotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Online psychoeducation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>12 weeks treatment with online psychoeducation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Face-to-face hypnotherapy</intervention_name>
    <description>12 weeks treatment with face-to-face hypnotherapy (6 individual, bi-weekly sessions)</description>
    <arm_group_label>Face-to-face hypnotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Online hypnotherapy</intervention_name>
    <description>12 weeks treatment with online hypnotherapy</description>
    <arm_group_label>Online hypnotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Online psychoeducation</intervention_name>
    <description>12 weeks treatment with online psychoeducation</description>
    <arm_group_label>Online psychoeducation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Age 16-65 years

          -  A diagnosis of IBS according to the Rome IV criteria

          -  In the presence of alarm symptoms, such as rectal blood loss, weight loss, anemia,
             first onset of symptoms above 50 years of age, patients will be first referred for
             further investigation by their treating physician to exclude organic disorders,
             conform current Dutch guidelines for IBS.

          -  Women in fertile age must use contraception or be postmenopausal for at least two
             years.

        Exclusion criteria:

          -  Insufficient command of the Dutch language

          -  No access to internet

          -  Evidence of current anxiety and/or depression disorder as defined by a score â‰¥10 on
             the GAD-7 and/or PHQ-9 questionnaire. In this case it is conceivable that the IBS
             symptoms are strongly related to psychopathology for which different treatment might
             be more appropriate.

          -  History of ulcerative colitis, Crohn's disease, coeliac disease or significant liver
             disease

          -  Major surgery to the lower gastrointestinal tract, such as partial or total colectomy,
             small bowel resection or partial or total gastrectomy

          -  Past or present radiotherapy to the abdomen

          -  Current pregnancy or lactation

          -  Using of psychoactive medication in case there's no stable dose for at least 3 months
             prior to inclusion

          -  Use of over-the-counter or prescription antidiarrheals, analgesics and laxatives in
             case there's no stable dose during the study period

          -  Hypnotherapy treatment received in the last 3 months prior to inclusion

          -  Using more than 20 units of alcohol per week

          -  Using drugs of abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A.A.M. Masclee, Prof., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anke Snijkers, MD</last_name>
    <phone>0031433882952</phone>
    <email>fortitude-intmed@maastrichtuniversity.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel Keszthelyi, MD, PhD</last_name>
    <email>daniel.keszthelyi@maastrichtuniversity.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medisch Centrum Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <state>Friesland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>H.J.A. Jebbink</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rijnstate</name>
      <address>
        <city>Arnhem</city>
        <state>Gelderland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>D.P. Hirsch</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gelderse Vallei</name>
      <address>
        <city>Ede</city>
        <state>Gelderland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>B.J.M. Witteman</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Keszthelyi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>Den Bosch</city>
        <state>Noord-Brabant</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>K. van Hee</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bernhoven</name>
      <address>
        <city>Uden</city>
        <state>Noord-Brabant</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>B.J.T. Haarhuis</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maxima Medisch Centrum</name>
      <address>
        <city>Veldhoven</city>
        <state>Noord-Brabant</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>J.W.A. Straathof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AMC</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>A.J. Bredenoord</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>VU Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>R.J.F. Felt-Bersma</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tergooi Hilversum</name>
      <address>
        <city>Hilversum</city>
        <state>Noord-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>B.D.J. van den Elzen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <state>Overijssel</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>J.J. Kolkman</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alrijne Ziekenhuis</name>
      <address>
        <city>Leiden</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>C.H.M. Clemens</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Martini Ziekenhuis</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>L.A. van der Waaij</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diakonessenhuis</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>A.H. Obernhoff-Klein Woolthuis</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>February 13, 2019</study_first_submitted>
  <study_first_submitted_qc>April 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2019</study_first_posted>
  <last_update_submitted>August 27, 2019</last_update_submitted>
  <last_update_submitted_qc>August 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

